Allergan's Patent Loophole Could Be a Huge Gift for Pfizer
The tribe has spoken.
On Friday, Allergan (NYSE: AGN) announced that the Saint Regis Mohawk Tribe now owns all patents for blockbuster dry-eye disease drug Restatis. Both parties should win from the deal. The tribe will receive millions of dollars upfront and in annual royalties. Allergan gets exclusive rights to continue marketing Restasis and now has a unique way of fending off potential generic threats to the drug.
There's at least one other potential winner: Pfizer (NYSE: PFE). Here's why the big drugmaker could benefit from taking a page out of Allergan's book.
Source: Fool.com
Merck & Co. Inc. Stock
€121.20
1.510%
The stock is one of the favorites of our community with 28 Buy predictions and 1 Sell predictions.
As a result the target price of 124 € shows a slightly positive potential of 2.31% compared to the current price of 121.2 € for Merck & Co. Inc..
